Posts Tagged ‘clinical translation’

Bench to Bedside for Biotherapeutics (B3) workshop: Translating science into the clinic

Author: Guest, 10/18/17

Shreya Shukla is a Development Scientist at CCRM. Her scientific interests lie at the intersection of T cell immunotherapy, gene editing and stem cell bioengineering. Shreya obtained her BSc in Biomedical Engineering from Georgia Institute of Technology and PhD from Dr. Peter Zandstra’s laboratory at University of Toronto (UofT) focusing on the scalable generation of…Read more

Five regenerative medicine workshops to attend this summer

Author: Guest, 05/15/17

Amin Adibi is a biomedical engineer and a health data analyst at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for…Read more

Filling the void: A scientist’s introduction to commercialization/clinical translation

Author: Holly Wobma, 04/26/17

For anybody who has invested a great deal of time into a research project, you probably feel a certain sense of expertise on the topic. Sure, it is impossible to know a whole field (every answer raises more questions), and lab work is rife with puzzlement and failures, but at the end of the day,…Read more

Improving ultrasound imaging may have applications in regenerative medicine

Author: Guest, 03/13/17

Andy Bell, a writer working with Toronto3dprinting, loves to write about different topics related to technological gadgets and gears. 3D printing is his current interest. Though ultrasound technology is commonly associated with the imaging of fetuses in the womb, its applications are much more than just imaging. The acoustic waves generated by ultrasound devices can…Read more

A new style of MSC immunotherapy – Instructions included

Author: Holly Wobma, 09/22/16

If you have been following stem cell news lately, you know that there have been several recent Food and Drug Administration (FDA) meetings regarding how to classify stem cells, which ultimately affects if and how they will be regulated. There are many medical practitioners, scientists, and patients who would like to see these therapies on…Read more

Right Turn: Animals, ethics and Orwell

Author: Stacey Johnson, 07/08/16

Much has been said on the topic of using animals for medical/scientific research. There are excellent and compelling arguments for and against the issue and my plan is to avoid taking a stand here. (You may be tempted to call me chicken, but that would be a really bad pun!) As polarizing as this topic…Read more

Immunotoxins: a surprisingly less toxic approach to stem cell transplants

Author: Holly Wobma, 07/06/16

It is often the case that to produce something ‘shiny,’ new and better, we must first get rid of the old. This is true even in the case of stem cell therapies. Hematopoietic stem cell (HSC) transplants have been around since the mid-twentieth century and are used to treat a broad range of diseases such…Read more

Highlights from the World Biomaterials Congress Part II: Stepping up delivery strategies

Author: Samantha Payne, 06/20/16

This post is the second of two covering the World Biomaterials Congress. To read my previous blog about the use of biomaterials to study cell behaviour and differentiation in vitro, please click here. This post will cover the use of biomaterials for in vivo delivery strategies. Cartilage, despite its essential role in the movement of…Read more

Update from the Clinic: March

Author: Mark Curtis, 04/28/16

Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and clinical study starts. A study of Vericel’s (VCEL) ixmyelocel-T…Read more

Cell Therapy Deal Review: March

Author: Mark Curtis, 04/25/16

Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma. Cellectis (CLLS) has already separated itself from the pack with UCART19, a universal CAR product targeting…Read more